Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559800 | 0.83 | MAP4K1 (0.38) | — | |
| SCHEMBL12696393 | 0.81 | PKM (0.39) | MLYCDMEN1KMT2ATDP1PKM | |
| SCHEMBL20516233 | 0.78 | KMT2A (0.38) | MEN1KMT2A | |
| SCHEMBL5761874 | 0.73 | NPSR1 (0.48) | KMT2ATDP1RAB9A | |
| SCHEMBL950861 | 0.72 | — | — | |
| SCHEMBL15195597 | 0.72 | — | — | |
| SCHEMBL31467466 | 0.71 | HCAR2 (0.38) | MLYCDDYRK1A | |
| Hydrochloric Acid SCHEMBL19384655 | 0.71 | NOTUM (0.40) | KMT2A | |
| SCHEMBL19384586 | 0.71 | — | — | |
| SCHEMBL169065 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017162611-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162611-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |